Table 3 Associations between the TNFα polymorphisms and clinical response.
Gene | Genotype | Steroid-free + PCDAI/PUCAI < 10 | OR | 95% CI | P value | CRP ≤0.5mg/dL + Calprotectin ≤ 150 μg/g + PCDAI/PUCAI < 10 | OR | 95% CI | P value | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
Yes n (%) | No n (%) | Yes n (%) | No n (%) | ||||||||
Infliximab | |||||||||||
TNFα rs1800629 −308 G>A | GG GA + AA | 38 (84.5) 2 (4.4) | 3 (6.7) 2 (4.4) | 12.6 | 1.28–124.5 | 0.03 | 20 (37) 1 (1.9) | 26 (48.1) 7 (13) | 5.38 | 0.61–47.4 | 0.13 |
TNFα rs361525 −238G>A | GG GA + AA | 32 (71.1) 8 (17.8) | 4 (8.9) 1 (2.2) | 1.00 | 0.09–10.2 | 1.00 | 28 (51.8) 5 (9.3) | 16 (29.6) 5 (9.3) | 0.57 | 0.14–2.28 | 0.42 |
TNFα rs1799724 −857C>T | CC CT + TT | 26 (57.8) 14 (31.1) | 3 (6.7) 2 (4.4) | 1.24 | 0.18–8.30 | 0.82 | 16 (29.6) 5 (9.3) | 20 (37) 13 (24.1) | 2.19 | 0.64–7.47 | 0.21 |
Adalimumab | |||||||||||
TNFα rs1800629 −308 G>A | GG GA + AA | 10 (55.5) 3 (16.7) | 4 (22.2) 1 (5.6) | 0.83 | 0.06–10.59 | 0.88 | 5 (26.3) 2 (10.5) | 10 (52.75) 2 (10.5) | 0.5 | 0.05–4.67 | 0.54 |
TNFα rs361525 −238G>A | GG GA + AA | 13 (72.2) 0 (0) | 4 (22.2) 1 (5.6) | 9.0 | 0.30–262 | 0.20 | 6 (31.6) 0 (0) | 12 (63.1) 1 (5.3) | 1.56 | 0.05–43.9 | 0.79 |
TNFα rs1799724 −857C>T | CC CT + TT | 9 (50) 4 (22.2) | 5 (27.8) 0 (0) | 0.19 | 0.008–4.28 | 0.29 | 5 (26.3) 1 (5.3) | 9 (47.4) 4 (21) | 2.22 | 0.19–25.7 | 0.52 |
